Cargando…
Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468451/ https://www.ncbi.nlm.nih.gov/pubmed/36087383 http://dx.doi.org/10.1016/j.tranon.2022.101528 |
| _version_ | 1784788414839652352 |
|---|---|
| author | Schjesvold, Fredrik H Bakker, Nicolaas A Sonneveld, Pieter |
| author_facet | Schjesvold, Fredrik H Bakker, Nicolaas A Sonneveld, Pieter |
| author_sort | Schjesvold, Fredrik H |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9468451 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Neoplasia Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94684512022-09-22 Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA Schjesvold, Fredrik H Bakker, Nicolaas A Sonneveld, Pieter Transl Oncol Letters to the Editor Neoplasia Press 2022-09-07 /pmc/articles/PMC9468451/ /pubmed/36087383 http://dx.doi.org/10.1016/j.tranon.2022.101528 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Letters to the Editor Schjesvold, Fredrik H Bakker, Nicolaas A Sonneveld, Pieter Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA |
| title | Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA |
| title_full | Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA |
| title_fullStr | Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA |
| title_full_unstemmed | Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA |
| title_short | Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA |
| title_sort | authors’ reply: perspective: the approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the fda |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468451/ https://www.ncbi.nlm.nih.gov/pubmed/36087383 http://dx.doi.org/10.1016/j.tranon.2022.101528 |
| work_keys_str_mv | AT schjesvoldfredrikh authorsreplyperspectivetheapprovalandwithdrawalofmelphalanflufenamidemelflufenimplicationsforthestateofthefda AT bakkernicolaasa authorsreplyperspectivetheapprovalandwithdrawalofmelphalanflufenamidemelflufenimplicationsforthestateofthefda AT sonneveldpieter authorsreplyperspectivetheapprovalandwithdrawalofmelphalanflufenamidemelflufenimplicationsforthestateofthefda |